Cargando…

Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials

BACKGROUND: We carried out a meta-analysis since there is not enough evidence to recommend for or against therapeutic-dose anticoagulation compared with thromboprophylaxis in noncritically ill patients hospitalized with Covid-19. METHODS: We performed a systematic literature search using PubMed, Emb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ena, Javier, Valls, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9435420/ https://www.ncbi.nlm.nih.gov/pubmed/36048371 http://dx.doi.org/10.1007/s10238-022-00876-3

Ejemplares similares

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin
por: Tao, Ende, et al.
Publicado: (2020)

Safety and Efficacy of Low Molecular Weight Heparin for Thromboprophylaxis in the Elderly: A Network Meta-Analysis of Randomized Clinical Trials
por: Yang, Hui-qin, et al.
Publicado: (2021)

Comparison of low-molecular-weight heparins in thromboprophylaxis of major orthopaedic surgery – randomized, prospective pilot study
por: Biławicz, Jan, et al.
Publicado: (2020)

Low-molecular weight heparin infusion as anticoagulation for haemodialysis
por: Wong, Steve Siu-Man, et al.
Publicado: (2016)

Fondaparinux Sodium Compared With Low‐Molecular‐Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta‐analysis
por: Kumar, Arun, et al.
Publicado: (2019)

Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials
por: Marcucci, Maura, et al.
Publicado: (2022)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
por: Tucker, Madeline, et al.
Publicado: (2021)

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review
por: Feng, Ke, et al.
Publicado: (2023)

Low molecular-weight heparin for thromboprophylaxis in patients undergoing gastric cancer surgery: an experience from one Korean institute
por: Choi, Sung Ho, et al.
Publicado: (2014)

Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study
por: Ferrandis, R., et al.
Publicado: (2023)

THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents
por: Greiner, Jeanette, et al.
Publicado: (2019)

The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study
por: Eman, Ali, et al.
Publicado: (2022)

Patients’ Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips
por: Harenberg, Job, et al.
Publicado: (2022)

Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial
por: Pai, Menaka, et al.
Publicado: (2018)

Therapeutically dosed low molecular weight heparins in renal impairment: a nationwide survey
por: Jaspers, Tessa Corrine Catherina, et al.
Publicado: (2022)

TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial
por: Klaassen, Irene L. M., et al.
Publicado: (2017)

Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?
por: Wijaya, Indra, et al.
Publicado: (2020)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation
por: Andrade, S.A., et al.
Publicado: (2012)

Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden
por: Lund, Lars Christian, et al.
Publicado: (2022)

Postpartum Heparin Thromboprophylaxis: More Harm Than Good
por: Kotaska, Andrew
Publicado: (2021)

MON-182 Increased Risk of Bleeding and Excessive Anticoagulation Using Standard Dose Low Molecular Weight Heparin (LMWH) in Cushing’s Syndrome
por: Haykal, Rasha, et al.
Publicado: (2020)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis
por: DU, JUN-DONG, et al.
Publicado: (2014)

Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection
por: Canoglu, Kadir, et al.
Publicado: (2020)

Safety of intermediate dose of low molecular weight heparin in COVID-19 patients
por: Mattioli, Massimo, et al.
Publicado: (2020)

Low Dose Low-Molecular-Weight Heparin for Thrombosis Prophylaxis: Systematic Review with Meta-Analysis and Trial Sequential Analysis
por: Eck, Ruben J., et al.
Publicado: (2019)

Comparative Efficacy of Direct Oral Anticoagulants and Low-Molecular-Weight Heparin in Cancer-Associated Thromboembolism: A Systematic Review and Meta-Analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Heparin/low molecular weight heparins: Thrombocytopenia: 7 case reports
Publicado: (2021)

Injection Site Erythema in a Patient on Therapeutic Anticoagulation with Low Molecular Weight Heparin after Mechanical Aortic Valve Replacement: A Rare Presentation of Heparin- and Protamine-Induced Thrombocytopenia
por: Holaubek, Caroline, et al.
Publicado: (2020)

Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing
por: Engelen, Matthias M., et al.
Publicado: (2022)

Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients
por: Pfrepper, Christian, et al.
Publicado: (2023)

Thromboprophylaxis with standard-dose vs. flexible-dose heparin for hospitalized COVID-19 patients: a target trial emulation
por: Martínez-Alés, Gonzalo, et al.
Publicado: (2022)

Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
por: Dimosiari, Athina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t57s9f6tcq0ctkg7vjehd4r0fk